Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
This article was originally published in The Pink Sheet Daily
Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.
You may also be interested in...
Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.